Quidel stock price target lowered to $55 by Raymond James on prudent guidance

Investing.com - Raymond (NSE:RYMD) James has lowered its price target on Quidel Corp . (NASDAQ:QDEL) to $55.00 from $60.00 while maintaining an Outperform rating on the stock. The new target represents significant upside potential from the current price of $23.68, with the stock trading near its 52-week low of $22.05. According to InvestingPro data, analyst targets for the stock range from $27 to $60.

The adjustment comes despite Quidel reporting what Raymond James described as "another strong and fairly clean quarter." The company’s revenues were approximately in line with expectations overall, with outperformance in the Labs segment, in-line respiratory revenues, and a timing-oriented shortfall in non-respiratory point-of-care products.

Margins exceeded expectations, with EBITDA reaching $107 million (17.4%) compared to the consensus estimate of $95 million (15.5%). Despite this strong performance, Quidel reiterated its guidance on major metrics, which Raymond James views as a prudent move given the "show me nature of the story."

Raymond James noted that underlying adjustments to its outlook include the removal of an assumed summer COVID spike in the third quarter, offset by improvements in foreign exchange, tariffs, and savings from Savanna.

The investment firm believes Quidel’s story "is clearly on track after Q2" from both top-line and margin perspectives, with expectations for "additional traction to build further." Despite the price target reduction, Raymond James sees "room for dramatic upside" to its new $55 target.

In other recent news, Quidel Ortho reported an impressive second quarter for 2025, with earnings per share (EPS) of $0.12, significantly surpassing the forecast of $0.0015, resulting in a 7900% surprise. The company’s revenue reached $614 million, slightly above expectations set by analysts. Despite these strong financial results, the stock experienced a decline, closing down by 1.78%. These developments highlight mixed investor sentiment surrounding the company’s performance. Additionally, there were no recent mergers or acquisitions announced by Quidel Ortho. Analyst firms have not provided any upgrades or downgrades in their latest reports on the company. These recent developments provide a factual snapshot of Quidel Ortho’s current financial standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.